Previous studies have revealed a significant correlation between Bcl-xL expression and carboplatin-resistance [8]–[10], and increased sensitivity to standard chemotherapeutic agents of ovarian cancer cell lines when Bcl-xL expression is inhibited [11]–[13]. The gene discussed is BCL2L1; the disease is ovarian cancer.